Списоклитературы
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from: www.ginasthma.org.
2. Федеральные клинические рекомендации. Бронхиальная астма. РРО. РААКИ. СоюзпедиатровРоссии, 2021, 114 с.
3. Rodrigo G.J., Neffen H., Castro-Rodriguez J.A. Efficacyandsafetyofsubcutaneousomalizumab vs placebo as addon therapy to corticosteroids for children and adults with asthma: a systematic review // Chest. 2011.Vol. 139.P. 28-35.
4. Chung K.F., Wenzel S.E., Brozek J.L., et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma // Eur. Respir. J. 2014.Vol. 43.P. 343-373.
5. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial // Lancet. 2012.Vol. 380.P. 651-659.
6. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma // N. Engl. J. Med. 2014. Vol. 371. P. 1198-1207.
7. Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma // N. Engl. J. Med. 2014. Vol. 371. P. 1189-1197.
8. Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlledasthma with elevatedblood eosinophil counts: results from multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials // Lancet Respir. Med. 2015.Vol. 3.P. 355-366.
9. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial // Lancet. 2016.Vol. 388.P. 2128-2141.
10. Bleecker E.R, FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multi-centre, placebo-controlled phase 3 trial // Lancet. 2016.Vol. 388.P. 2115-2127.
11. Castro M., Corren J., Pavord I.D. et al. Dupilumab efficacy and safety in moderate-tosevere uncontrolled asthma // N. Engl. J. Med. 2018.Vol. 378. N. 26.P. 2486-2496.
12. Rabe K.F. et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma // N. Engl. J. Med. 2018.Vol. 378.P. 2475-2485.
13. Zayed Y. et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials // J. Asthma. 2018 Oct 1.P. 1-10.
14. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. A GINA pocket guide for health professionals. April 2019, v 2.0. Available on the www.ginasthma.org.
15. Bachert C. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials // Lancet. 2019. Vol. 394. P. 1638-1650.